164 related articles for article (PubMed ID: 23411683)
1. Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study.
Jain V; Jain B; Tiwari P; Saini J; Jain UK; Pandey RS; Kumar M; Katare OP; Chandra R; Madan J
Anticancer Drugs; 2013 Apr; 24(4):327-36. PubMed ID: 23411683
[TBL] [Abstract][Full Text] [Related]
2. Microtubule-binding natural products for cancer therapy.
Yue QX; Liu X; Guo DA
Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation.
Yin YM; Cui FD; Mu CF; Choi MK; Kim JS; Chung SJ; Shim CK; Kim DD
J Control Release; 2009 Dec; 140(2):86-94. PubMed ID: 19709639
[TBL] [Abstract][Full Text] [Related]
4. Microtubule dynamics as a target in oncology.
Risinger AL; Giles FJ; Mooberry SL
Cancer Treat Rev; 2009 May; 35(3):255-61. PubMed ID: 19117686
[TBL] [Abstract][Full Text] [Related]
5. Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.
Henary M; Narayana L; Ahad S; Gundala SR; Mukkavilli R; Sharma V; Owens EA; Yadav Y; Nagaraju M; Hamelberg D; Tandon V; Panda D; Aneja R
Biochem Pharmacol; 2014 Nov; 92(2):192-205. PubMed ID: 25124704
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class.
Owellen RJ; Hartke CA; Dickerson RM; Hains FO
Cancer Res; 1976 Apr; 36(4):1499-502. PubMed ID: 1260766
[TBL] [Abstract][Full Text] [Related]
7. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
8. Anti-Microtubule Drugs.
Florian S; Mitchison TJ
Methods Mol Biol; 2016; 1413():403-21. PubMed ID: 27193863
[TBL] [Abstract][Full Text] [Related]
9. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting.
Sawant RR; Torchilin VP
Mol Membr Biol; 2010 Oct; 27(7):232-46. PubMed ID: 20929339
[TBL] [Abstract][Full Text] [Related]
10. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
[TBL] [Abstract][Full Text] [Related]
12. Microtubule drugs: action, selectivity, and resistance across the kingdoms of life.
Dostál V; Libusová L
Protoplasma; 2014 Sep; 251(5):991-1005. PubMed ID: 24652407
[TBL] [Abstract][Full Text] [Related]
13. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
14. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Lopus M; Naik PK
Pharmacol Rep; 2015 Feb; 67(1):56-62. PubMed ID: 25560576
[TBL] [Abstract][Full Text] [Related]
15. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously.
Gapud EJ; Bai R; Ghosh AK; Hamel E
Mol Pharmacol; 2004 Jul; 66(1):113-21. PubMed ID: 15213302
[TBL] [Abstract][Full Text] [Related]
16. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics.
Kanakkanthara A; Teesdale-Spittle PH; Miller JH
Anticancer Agents Med Chem; 2013 Jan; 13(1):147-58. PubMed ID: 22583426
[TBL] [Abstract][Full Text] [Related]
17. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
18. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
Aparicio LM; Pulido EG; Gallego GA
Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
[TBL] [Abstract][Full Text] [Related]
19. Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine.
Cui SX; Nie SF; Li L; Wang CG; Pan WS; Sun JP
Drug Dev Ind Pharm; 2009 May; 35(5):603-11. PubMed ID: 19040178
[TBL] [Abstract][Full Text] [Related]
20. Targeting microtubules for cancer chemotherapy.
Zhou J; Giannakakou P
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
